UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Precision oncology: origins, optimism, and potential

The lancet oncology, 2016-02, Vol.17 (2), p.e81-e86

2016

Volltextzugriff (PDF)

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Seminars in oncology, 2017-12, Vol.44 (6), p.395-403

2017

Volltextzugriff (PDF)

Cancer Drugs in the United States: Justum Pretium—The Just Price

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3600-3604

2013

Volltextzugriff (PDF)

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

Clinical cancer research, 2010-12, Vol.16 (24), p.5972-5980

2010

Volltextzugriff (PDF)

Precision Oncology: A Strategy we were not Ready to Deploy

Seminars in oncology, 2016-02, Vol.43 (1), p.9-12

2016

Volltextzugriff (PDF)

Strategies for reversing drug resistance

Oncogene, 2003-10, Vol.22 (47), p.7512-7523

2003

Volltextzugriff (PDF)

Gefitinib and Erlotinib in Metastatic Non‐Small Cell Lung Cancer: A Meta‐Analysis of Toxicity and Efficacy of Randomized Clinical Trials

The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.400-410

2015

Volltextzugriff (PDF)

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood, 2011-06, Vol.117 (22), p.5827-5834

2011

Volltextzugriff (PDF)

The High Cost of Ignorance in Oncology

Seminars in oncology, 2016-12, Vol.43 (6), p.623-624

2016

Volltextzugriff (PDF)

Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?

Clinical cancer research, 2007-12, Vol.13 (24), p.7280-7287

2007

Volltextzugriff (PDF)

Mechanisms of resistance to PARP inhibitors--three and counting

Cancer discovery, 2013-01, Vol.3 (1), p.20-23

2013

Volltextzugriff (PDF)

Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia

The New England journal of medicine, 2012-09, Vol.367 (10), p.922-930

2012

Volltextzugriff (PDF)

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5410-5417

2009

Volltextzugriff (PDF)

Pseudo-progressing to an unmet need

Seminars in oncology, 2017-02, Vol.44 (1), p.1-2

2017

Volltextzugriff (PDF)

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4619-4629

2009

Volltextzugriff (PDF)

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

The New England journal of medicine, 2012-06, Vol.366 (23), p.2189-2197

2012

Volltextzugriff (PDF)

Waiting for ASCO to “Walk the Walk”

The oncologist (Dayton, Ohio), 2023-11, Vol.28 (11), p.921-924

Fojo, Tito

2023

Volltextzugriff (PDF)

Seminars in oncology 50th anniversary

Seminars in oncology, 2024-02, Vol.51 (1-2), p.1-1

Fojo, Tito

2024

Volltextzugriff (PDF)

Moving a Pioneer Journal Into the Future

Seminars in oncology, 2016-02, Vol.43 (1), p.1-1

2016

Volltextzugriff (PDF)

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors

Surgery, 2013-12, Vol.154 (6), p.1224-1229

2013

Volltextzugriff (PDF)

MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy

Cancer, 2011-04, Vol.117 (8), p.1630-1639

2011

Volltextzugriff (PDF)

The flaws in assessing and reporting the toxicities of oral targeted therapies: Everolimus as an example

Seminars in oncology, 2023-02, Vol.50 (1-2), p.1-6

Fojo, Tito

2023

Volltextzugriff (PDF)

The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward

Seminars in oncology, 2022-12, Vol.49 (6), p.427-428

Fojo, Tito

2022

Volltextzugriff (PDF)

The flaws in assessing and reporting the toxicities of oral targeted therapies

Seminars in oncology, 2023-02, Vol.50 (1-2), p.1-6

Fojo, Tito

2023

Volltextzugriff (PDF)

Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials

Clinical trials (London, England), 2021-12, Vol.18 (6), p.690-698

2021

Volltextzugriff (PDF)

1 – 25 von 390

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(375)
Mit Volltextzugriff
(351)

Publikationsform

Sprache

Englisch
(390)

Erscheinungsjahr

n.n

Thema

Science & Technology
(265)
Life Sciences & Biomedicine
(259)
Humans
(235)
Oncology
(193)
Biological And Medical Sciences
(90)
Female
(87)
Medical Sciences
(84)
Antineoplastic Agents
(62)
Male
(62)
Pharmacology. Drug Treatments
(57)
Middle Aged
(53)
Adult
(49)
Neoplasms - Drug Therapy
(47)
Tumors
(44)
Tumor Cells, Cultured
(43)
Cancer
(41)
Chemotherapy
(39)
Treatment Outcome
(37)
Aged
(36)
Antineoplastic Agents - Therapeutic Use
(36)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Precision oncology: origins, optimism, and potential

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Cancer Drugs in the United States: Justum Pretium—The Just Price

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

Precision Oncology: A Strategy we were not Ready to Deploy

Strategies for reversing drug resistance

Gefitinib and Erlotinib in Metastatic Non‐Small Cell Lung Cancer: A Meta‐Analysis of Toxicity and Efficacy of Randomized Clinical Trials

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

The High Cost of Ignorance in Oncology

Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?

Mechanisms of resistance to PARP inhibitors--three and counting

Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Pseudo-progressing to an unmet need

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Waiting for ASCO to “Walk the Walk”

Seminars in oncology 50th anniversary

Moving a Pioneer Journal Into the Future

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors

MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy

The flaws in assessing and reporting the toxicities of oral targeted therapies: Everolimus as an example

The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward

The flaws in assessing and reporting the toxicities of oral targeted therapies

Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials

Aktive Filter

Suchergebnisse filtern